Table 2.

Odds ratio table showing logistic regression associations with virologic failure

Predictor	Estimated Odds ratio for virologic failure (95% CI)	P-value for overall differences Sig. < 0.05
Race/ethnicity
Black, non-Hispanic vs. White, non-Hispanic	2.2 (1.3, 3.8)	0.002
Hispanic vs. White, non-Hispanic	1.05 (0.55, 2.0)
Othera vs. White, non-Hispanic	0.91 (0.14, 3.5)
IV Drug Use
Current/Previous vs. Never	1.5 (0.71, 3.1)	0.19
Sex
Female vs. Male	0.7 (0.36, 1.3)	0.18
Assigned NRTIs
ABC/3TC vs. TDF/FTC	1.02 (0.65, 1.6)	0.91
Age (every 5 years)	0.86 (0.76, 0.96)	0.002
Screening HIV-1 RNA Stratification
≥ 100,000 vs. < 100,000 copies/mL	1.3 (0.83, 2.1)	0.16
Efavirenz Concentration Group & Weight Interactionb, c
Low vs. Within at 1st quartile (25%) of weight	3.18 (1.60, 6.29)	0.036
Low vs. Within at median (50%) of weight	2.28 (1.29, 4.04)
Low vs. Within at 3rd quartile (75%) of weight	1.41 (0.69, 2.89)
Low vs. High at 1st quartile (25%) of weight	5.41 (2.16, 13.57)
Low vs. High at median (50%) of weight	3.66 (1.59, 8.42)
Low vs. High at 3rd quartile (75%) of weight	2.07 (0.71, 6.08)

NRTIs, nucleos[t]ide reverse transcriptase inhibitors; TDF/FTC, tenofovir disproxil fumurate/emtricitabine; ABC/3TC, abacavir/lamivudine.

^a11 Asian, 8 Native American/Alaskan Natives, 5 subjects reporting more than one race

^bLow efavirenz concentration group is combined with the both group

^cP-value from continuous version of the weight covariate.